The impact of current immunosuppression strategies in renal transplantation on the field of reconstructive transplantation

Journal of Reconstructive Microsurgery

Volumn 28, Issue 1, 2012, Pages 7-19

  Chang, Jeff ^a   Davis, Connie L ^b   Mathes, David W ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

composite tissue allotransplantation; face transplantation; Immunosuppression

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ALLOGRAFT; ARTICLE; AVASCULAR NECROSIS; BONE PAIN; COMPOSITE TISSUE ALLOGRAFT TRANSPLANTATION; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIARRHEA; DRUG INDUCED HEADACHE; FACIAL TRANSPLANTATION; GOUT; GRAFT REJECTION; HAND SURGERY; HAND TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MEDICAL LITERATURE; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; NONHUMAN; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREMOR; VOMITING;

EVIDENCE-BASED MEDICINE; FACIAL TRANSPLANTATION; FEMALE; GRAFT REJECTION; HAND; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; MALE; RECONSTRUCTIVE SURGICAL PROCEDURES; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 84856241320     PISSN: 0743684X     EISSN: 10988947     Source Type: Journal    
DOI: 10.1055/s-0031-1285988     Document Type: Article

References (77)

1. Garcia VD, Carvalho DB, Gonalves RT., et al. Randomized trial of early corticosteroid reduction vs. regular-dose corticosteroid maintenance in combination with tacrolimus and mycophenolate mofetil in living donor kidney transplant recipients: the Brazilian CORRETA trial. Clin Transplant: 2010; 24 4 E109 E115
2. Merrill JP, Murray JE, Harrison JH, Guild WR. Successful homotransplantation of the human kidney between identical twins. J Am Med Assoc: 1956; 160 4 277 282
3. Whitaker IS, Duggan EM, Alloway RR., et al. Composite tissue allotransplantation: a review of relevant immunological issues for plastic surgeons. J Plastic Reconstr Aesthet Surg: 2008; 61 5 481 492 (Pubitemid 351635903)
4. Forsythe JL. ATGa polyclonal sledgehammer? Transpl Immunol: 1994; 2 2 148 152
5. Vincenti F, Kirkman R, Light S., et al. Daclizumab Triple Therapy Study Group Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med: 1998; 338 3 161 165 (Pubitemid 28041863)
6. Hardinger KL, Rhee S, Buchanan P., et al. A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. Transplantation: 2008; 86 7 947 952
7. Cantarovich M, Durrbach A, Hiesse C, Ladouceur M, Benoit G, Charpentier B. 20-year follow-up results of a randomized controlled trial comparing antilymphocyte globulin induction to no induction in renal transplant patients. Transplantation: 2008; 86 12 1732 1737
8. Tian JH, Wang X, Yang KH, Liu AP, Luo XF, Zhang J. Induction with and without antithymocyte globulin combined with cyclosporine/tacrolimus-based immunosuppression in renal transplantation: a meta-analysis of randomized controlled trials. Transplant Proc: 2009; 41 9 3671 3676
9. Calne R, Friend P, Moffatt S., et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet: 1998; 351 9117 1701 1702 (Pubitemid 28254534)
10. Ciancio G, Burke GW III. Alemtuzumab (Campath-1H) in kidney transplantation. Am J Transplant: 2008; 8 1 15 20
11. Farney A, Sundberg A, Moore P., et al. A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation. Clin Transplant: 2008; 22 1 41 49 (Pubitemid 351150001)
12. Schadde E, D'Alessandro AM, Knechtle SJ., et al. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death. Transpl Int: 2008; 21 7 625 636 (Pubitemid 351852761)
13. Ciancio G, Burke GW, Gaynor JJ., et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant: 2008; 22 2 200 210 (Pubitemid 351420014)
14. Ciancio G, Gaynor JJ, Roth D., et al. Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation. Transplant Proc: 2010; 42 9 3503 3506
15. Thomas PG, Woodside KJ, Lappin JA, Vaidya S, Rajaraman S, Gugliuzza KK. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. Transplantation: 2007; 83 11 1509 1512 (Pubitemid 46934076)
16. Tan HP, Donaldson J, Basu A., et al. Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up. Am J Transplant: 2009; 9 2 355 366
17. Kandus A, Arnol M, Omahen K., et al. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study. Transplantation: 2010; 89 8 1022 1027
18. Webster AC, Ruster LP, McGee R., et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev: 2010; (1) CD003897
19. Laftavi MR, Alnimri M, Weber-Shrikant E., et al. Low-dose rabbit antithymocyte globulin versus basiliximab induction therapy in low-risk renal transplant recipients: 8-year follow-up. Transplant Proc: 2011; 43 2 458 461
20. Immunosuppression Use for Induction. 1999 to 2008 Recipients with Kidney Transplants. (2009). SRTR Database. Retrieved from http://optn.transplant.hrsa. gov/ar2009/506a-ki.htm
21. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ: 2005; 331 7520 810
22. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation: 2006; 81 9 1234 1248
23. Weir MR, Mulgaonkar S, Chan L., et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int: 2011; 79 8 897 907
24. Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, Grinyo J. FREEDOM Study Group. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant: 2008; 8 2 307 316
25. Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P.; Astellas Corticosteroid Withdrawal Study Group A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg: 2008; 248 4 564 577
26. Augustine JJ, Hricik DE. Steroid withdrawal: moving on to the next questions. Am J Transplant: 2009; 9 1 3 4
27. Luan FL, Steffick DE, Gadegbeku C, Norman SP, Wolfe R, Ojo AO. Graft and patient survival in kidney transplant recipients selected for de novo steroid-free maintenance immunosuppression. Am J Transplant: 2009; 9 1 160 168
28. Padiyar A, Augustine JJ, Bodziak KA, Aeder M, Schulak JA, Hricik DF. Influence of African-American ethnicity on acute rejection after early steroid withdrawal in primary kidney transplant recipients. Transplant Proc: 2010; 42 5 1643 1647
29. Laftavi MR, Stephan R, Stefanick B., et al. Randomized prospective trial of early steroid withdrawal compared with low-dose steroids in renal transplant recipients using serial protocol biopsies to assess efficacy and safety. Surgery: 2005; 137 3 364 371 (Pubitemid 40312216)
30. Heilman RL, Reddy KS, Mazur MJ., et al. Acute rejection risk in kidney transplant recipients on steroid-avoidance immunosuppression receiving induction with either antithymocyte globulin or basiliximab. Transplant Proc: 2006; 38 5 1307 1313
31. Heilman RL, Chakkera HA, Reddy KS., et al. Clinical factors associated with graft fibrosis in kidney-transplant recipients on steroid-avoidance immunosuppression. Clin Transplant: 2008; 22 3 309 315 (Pubitemid 351689661)
32. Heilman RL, Devarapalli Y, Chakkera HA., et al. Impact of subclinical inflammation on the development of interstitial fibrosis and tubular atrophy in kidney transplant recipients. Am J Transplant: 2010; 10 3 563 570
33. Pascual J, Zamora J, Galeano C, Royuela A, Quereda C. Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev: 2009; (1) CD005632
34. Immunosuppression Use for Induction by Discharge Regimen. 2004 to 2008 Recipients with Kidney Transplants. (2009). SRTR Database. Retrieved from http://optn.transplant.hrsa.gov/ar2009/506b-ki.htm
35. Dantal J, Berthoux F, Moal MC., et al; RAD A2420 Study Group. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transpl Int: 2010; 23 11 1084 1093 10.1111/j.1432-2277.2010.01094.x
36. Devauchelle B, Badet L, Lengel B., et al. First human face allograft: early report. Lancet: 2006; 368 9531 203 209 (Pubitemid 44037773)
37. Lantieri L, Meningaud JP, Grimbert P., et al. Repair of the lower and middle parts of the face by composite tissue allotransplantation in a patient with massive plexiform neurofibroma: a 1-year follow-up study. Lancet: 2008; 372 9639 639 645
38. Guo S, Han Y, Zhang X., et al. Human facial allotransplantation: a 2-year follow-up study. Lancet: 2008; 372 9639 631 638
39. Siemionow M, Papay F, Alam D., et al. Near-total human face transplantation for a severely disfigured patient in the USA. Lancet: 2009; 374 9685 203 209
40. Pomahac B, Pribaz J, Eriksson E., et al. Restoration of facial form and function after severe disfigurement from burn injury by a composite facial allograft. Am J Transplant: 2011; 11 2 386 393
41. Mathew JM, Garcia-Morales R, Fuller L., et al. Donor bone marrow-derived chimeric cells present in renal transplant recipients infused with donor marrow. I. Potent regulators of recipient antidonor immune responses. Transplantation: 2000; 70 12 1675 1682 (Pubitemid 32064819)
42. Sheil AG, Moseley RV, Murray JE. Differential skin and renal homograft survival in dogs on immunosuppressive therapy. Surg Forum: 1964; 15 166 168
43. Lee WP, Yaremchuk MJ, Pan YC, Randolph MA, Tan CM, Weiland AJ. Relative antigenicity of components of a vascularized limb allograft. Plast Reconstr Surg: 1991; 87 3 401 411
44. Kuhr CS, Yunusov M, Sale G, Loretz C, Storb R. Long-term tolerance to kidney allografts in a preclinical canine model. Transplantation: 2007; 84 4 545 547 (Pubitemid 47312168)
45. Dubernard JM, Lengel B, Morelon E., et al. Outcomes 18 months after the first human partial face transplantation. N Engl J Med: 2007; 357 24 2451 2460 (Pubitemid 350272784)
46. Pell G, Xu Y, Khoury N, Mougenot B, Rondeau E. Thrombotic microangiopathy in marginal kidneys after sirolimus use. Am J Kidney Dis: 2005; 46 6 1124 1128 (Pubitemid 41690239)
47. Moren M, Testelin S, Petruzzo P., et al. New Partial Face Allograft Transplantation: Report on First Six Months [Abstract]. American Society for Reconstructive Transplant (ASRT). Chicago, IL; Nov 2010.
48. Petruzzo P, Lanzetta M, Dubernard JM., et al. The International Registry on Hand and Composite Tissue Transplantation. Transplantation: 2010; 90 12 1590 1594
49. Jones JW, Gruber SA, Barker JH, Breidenbach WC. Louisville Hand Transplant Team. Successful hand transplantation. One-year follow-up. N Engl J Med: 2000; 343 7 468 473 (Pubitemid 30646486)
50. Breidenbach WC, Gonzales NR, Kaufman CL, Klapheke M, Tobin GR, Gorantla VS. Outcomes of the first 2 American hand transplants at 8 and 6 years posttransplant. J Hand Surg Am: 2008; 33 7 1039 1047
51. Ravindra KV, Buell JF, Kaufman CL., et al. Hand transplantation in the United States: experience with 3 patients. Surgery: 2008; 144 4 638 643 discussion 643644
52. Dubernard JM, Owen E, Herzberg G., et al. Human hand allograft: report on first 6 months. Lancet: 1999; 353 9161 1315 1320 (Pubitemid 29178782)
53. Petruzzo P, Revillard JP, Kanitakis J., et al. First human double hand transplantation: efficacy of a conventional immunosuppressive protocol. Clin Transplant: 2003; 17 5 455 460 (Pubitemid 37236120)
54. Dubernard JM, Petruzzo P, Lanzetta M., et al. Functional results of the first human double-hand transplantation. Ann Surg: 2003; 238 1 128 136 (Pubitemid 38176417)
55. Petruzzo P, Badet L, Gazarian A., et al. Bilateral hand transplantation: six years after the first case. Am J Transplant: 2006; 6 7 1718 1724 (Pubitemid 43945815)
56. Jabecki J, Kaczmarzyk L, Patrzaek D., et al. First Polish Hand Allograft 6-month report. Pol Przegl Chir: 2007; 79 3 232 238
57. Jablecki J, Kaczmarzyk L, Patrzaek D, Domanasiewicz A, Boratyska Z. First Polish forearm transplantation: report after 17 months. Transplant Proc: 2009; 41 2 549 553
58. Jablecki J, Kaczmarzyk L, Domanasiewicz A, Chelmonski A, Boratynska M, Patrzalek D. First Polish forearm transplantation - final report (outcome after 4 years). Ann Transplant: 2010; 15 2 61 67
59. Cavadas PC, Landin L, Ibaez J. Bilateral hand transplantation: result at 20 months. J Hand Surg Eur Vol: 2009; 34 4 434 443
60. Landin L, Cavadas PC, Garcia-Cosmes P, Thione A, Vera-Sempere F. Perioperative ischemic injury and fibrotic degeneration of muscle in a forearm allograft: functional follow-up at 32 months post transplantation. Ann Plast Surg: 2011; 66 2 202 209
61. Piza-Katzer H, Ninkovic M, Pechlaner S, Gabl M, Ninkovic M, Hussl H. Double hand transplantation: functional outcome after 18 months. J Hand Surg [Br]: 2002; 27 4 385 390
62. Schneeberger S, Ninkovic M, Piza-Katzer H., et al. Status 5 years after bilateral hand transplantation. Am J Transplant: 2006; 6 4 834 841 (Pubitemid 43345022)
63. Schneeberger S, Kreczy A, Brandacher G, Steurer W, Margreiter R. Steroid- and ATG-resistant rejection after double forearm transplantation responds to Campath-1H. Am J Transplant: 2004; 4 8 1372 1374 (Pubitemid 39013588)
64. Schneeberger S, Ninkovic M, Gabl M., et al. First forearm transplantation: outcome at 3 years. Am J Transplant: 2007; 7 7 1753 1762 (Pubitemid 46905428)
65. Schneeberger S, Gorantla VS, van Riet RP., et al. Atypical acute rejection after hand transplantation. Am J Transplant: 2008; 8 3 688 696 (Pubitemid 351287537)
66. Brandacher G, Ninkovic M, Piza-Katzer H., et al. The Innsbruck hand transplant program: update at 8 years after the first transplant. Transplant Proc: 2009; 41 2 491 494
67. Petruzzo P, Lanzetta M, Dubernard JM., et al. The international registry on hand and composite tissue transplantation. Transplantation: 2008; 86 4 487 492
68. Breidenbach WC. The Louisville Experience. American Society for Reconstructive Transplant (ASRT). Chicago, IL; Nov 2010.
69. Landin L, Cavadas PC, Ibaez J, Roger I. Malignant skin tumor in a composite tissue (bilateral hand) allograft recipient. Plast Reconstr Surg: 2010; 125 1 20e 21e
70. Cavadas PC. The Spanish Experience. International Hand and Composite Tissue Allograft Society (IHCTAS). Atlanta, GA; Mar 2011.
71. Yusen RD, Shearon TH, Qian Y., et al. Lung transplantation in the United States, 1999-2008. Am J Transplant: 2010; 10(4 Pt 2) 1047 1068
72. Mazariegos GV, Steffick DE, Horslen S., et al. Intestine transplantation in the United States, 1999-2008. Am J Transplant: 2010; 10(4 Pt 2) 1020 1034
73. Foster RD, Fan L, Neipp M., et al. Donor-specific tolerance induction in composite tissue allografts. Am J Surg: 1998; 176 5 418 421 (Pubitemid 29021539)
74. Siemionow MZ, Izycki DM, Zielinski M. Donor-specific tolerance in fully major histocompatibility major histocompatibility complex-mismatched limb allograft transplants under an anti-alphabeta T-cell receptor monoclonal antibody and cyclosporine A protocol. Transplantation: 2003; 76 12 1662 1668 (Pubitemid 38032410)
75. Kuo YR, Huang CW, Goto S., et al. Alloantigen-pulsed host dendritic cells induce T-cell regulation and prolong allograft survival in a rat model of hindlimb allotransplantation. J Surg Res: 2009; 153 2 317 325
76. Mathes DW, Randolph MA, Solari MG., et al. Split tolerance to a composite tissue allograft in a swine model. Transplantation: 2003; 75 1 25 31 (Pubitemid 36139690)
77. Hettiaratchy S, Melendy E, Randolph MA., et al. Tolerance to composite tissue allografts across a major histocompatibility barrier in miniature swine. Transplantation: 2004; 77 4 514 521 (Pubitemid 38282804)